3. Tools for Vaccine Design: Prediction and Validation of Highly Immunogenic and Conserved Class II Epitopes and Development of Epitope-Driven Vaccines

  1. Manmohan Singh and
  2. Indresh K. Srivastava
  1. Anne S. De Groot,
  2. Matthew Ardito,
  3. Ryan Tassone,
  4. Paul Knopf,
  5. Leonard Moise and
  6. William Martin

Published Online: 6 JUN 2011

DOI: 10.1002/9781118023648.ch3

Development of Vaccines: From Discovery to Clinical Testing

Development of Vaccines: From Discovery to Clinical Testing

How to Cite

De Groot, A. S., Ardito, M., Tassone, R., Knopf, P., Moise, L. and Martin, W. (2011) Tools for Vaccine Design: Prediction and Validation of Highly Immunogenic and Conserved Class II Epitopes and Development of Epitope-Driven Vaccines, in Development of Vaccines: From Discovery to Clinical Testing (eds M. Singh and I. K. Srivastava), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9781118023648.ch3

Editor Information

  1. Novartis Vaccines, Cambridge, Massachusetts, USA

Author Information

  1. Epivax, Inc., Providence, Rhode Island, USA

Publication History

  1. Published Online: 6 JUN 2011
  2. Published Print: 18 JUL 2011

ISBN Information

Print ISBN: 9780470256374

Online ISBN: 9781118023648

SEARCH

Keywords:

  • vaccine design tools, prediction and validation - immunogenic, conserved class II epitopes, epitope-driven vaccines;
  • immunoinformatics tools, vaccine design problem - epitope-based IDV, T-cell help for antibody-directed vaccines;
  • approaches, efficacy and reactivity - immunogenic consensus sequence (ICS) T helper epitopes, composite antigens

Summary

This chapter contains sections titled:

  • Introduction

  • Applying Immunoinformatics Tools to the Problem of Vaccine Design

  • Epitope-Driven Approach to Vaccine Development

  • Vaccine Design Tools

  • Immunogenic Consensus Sequence (ICS) Vaccines

  • ICS Protein-Based Vaccines

  • Potential Pitfalls: Advantages and Disadvantages of IDV

  • References